(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología terapia génica > DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista >

Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity
Autor(es) : Tirapu, I. (Íñigo)
Mazzolini, G. (Guillermo)
Rodriguez-Calvillo, M. (Mercedes)
Arina, A. (Ainhoa)
Palencia, B. (Belén)
Gabari, I. (Izaskun)
Melero, I. (Ignacio)
Palabras clave : Immunotherapy
Dendritic cells
Costimulation
CTLA-4
4-1BB
CD40
Cytokines
Fecha incorporación: 2002
Editorial : Springer Verlag
Versión del editor: http://www.aite.wroclaw.pl/journals/aite/2002_50/1.html
ISSN: 1661-4917
Cita: Tirapu I, Mazzolini G, Rodriguez-Calvillo M, Arina A, Palencia B, Gabari I, et al. Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity. Arch Immunol Ther Exp (Warsz) 2002;50(1):13-18.
Resumen
Cellular immune responses can destroy cancer cells, achieving the cure of experimental malignancies. An expanding wealth of knowledge on the molecular basis of how to prime and amplify a T cell response has fueled a number of strategies successful at treating established tumors (rather than merely preventing tumor grafting). The most efficacious approaches operate at different stages, including: 1) priming the immune response using tumor antigen-expressing dendritic cells or tumor cells transfected with genes that render them immunogenic, 2) sustaining and amplifying immunity using agonistic monoclonal antibodies against costimulatory molecules or immune-potentiating cytokines, and 3) eliminating mechanisms that self-regulate the strength of the immune response, such as inhibitory receptors or regulatory T cells. A rational combination of such approaches holds great hope for cumulative and synergistic effects, but there is also evidence that they can open the flood-gates for unwanted inflammatory reactions. The next decade can be envisioned as the time when the first reproducibly efficacious combination regimes for cancer immunotherapy will become available and widely used in the clinic, as clinicians learn the best strategies and try to harness their potentially damaging effects.
Enlace permanente: http://hdl.handle.net/10171/21801
Aparece en las colecciones: DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista

Ficheros en este registro:
Fichero:  ArchImmunolTheraExp20025013.pdf
Descripción: 
Tamaño:  148,16 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.